Saturday 17 October 2026
Export MDLN’s income statement to Excel — free account
Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7% and free cash flow grew 3.42%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
35.96
0.61
−1.67%
Follow MDLN
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Altman Z-Score |
2.25 | — | — |
P/S ratio |
0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
2.84 | — | — |
P/FCF ratio |
10.06 | 0.00 | 0.00 |
P/Operating CF |
19.51 | 0.00 | 0.00 |
Beneish M-Score |
(2.38) | — | — |
P/B ratio |
1.76 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
10.16 | 3.76 | 3.76 |
EV/FCF |
13.20 | 4.66 | 4.66 |
Quick Ratio |
2.20 | 1.40 | — |
Current Ratio |
4.29 | 3.39 | — |
Net Debt/EBITDA |
3.24 | 5.08 | 0.00 |
Debt/Assets |
32.64% | 45.84% | 0.00% |
Debt/Equity |
0.65 | 1.02 | 0.00 |
Asset Turnover |
0.76 | 1.42 | 0.00 |
Operating CF/Net income |
1.50 | 1.47 | 7.20 |
Capex/Depreciation |
(0.42) | (0.33) | (0.25) |
Interest Coverage |
2.72 | 2.48 | 1.28 |
| 6.54% | 0.00% | 0.00% | |
| 3.11% | 6.67% | 0.00% | |
ROIC |
4.62% | 4.13% | 0.00% |
Return on Tangible Assets |
8.94% | 11.51% | 0.00% |
Average Days of Receivables |
45.36 | 46.06 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
15.91% | 16.11% | 16.65% |
Intangible Assets out of Total Assets |
0.57 | 0.63 | 0.00 |
Share Based Compensation of Revenue |
0.27% | 0.24% | 0.34% |
Graham Net Nets |
(0.25) | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
9.94% | 0.00% | 0.00% |
Revenue per Share |
35.10 | 0.00 | 0.00 |
Operating CF per Share |
2.15 | 0.00 | 0.00 |
Capex per Share |
(0.55) | 0.00 | 0.00 |
Free Cash Flow per Share |
1.60 | 0.00 | 0.00 |
Cash per Share |
2.39 | 0.00 | — |
Shareholders Equity per Share |
23.81 | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | — |
Book value per Share |
23.81 | 0.00 | 0.00 |
Free Cash Flow |
1,297.00 | 1,415.00 | 1,410.00 |
Working Capital |
8,189.00 | 5,832.00 | — |
Capital Expenditures |
(447.00) | (354.00) | (275.00) |
Net Current Asset Value |
(8,519.00) | (11,548.00) | 0.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.22 | 0.23 | 0.00 |
Cash ROIC |
3.84% | 4.31% | 0.00% |
Accounts Receivable Turnover |
8.42 | 0.00 | 0.00 |
Accounts Payable Turnover |
22.86 | 0.00 | 0.00 |
Inventory Turnover |
4.53 | 0.00 | 0.00 |
Average Days of Payables |
16.77 | 17.12 | 0.00 |
Days of Inventory on Hand |
83.23 | 87.77 | 0.00 |
Average Receivables |
3,376.00 | — | — |
Average Payables |
915.00 | — | — |
Average Inventory |
4,612.50 | — | — |
Average Assets |
37,231.00 | 17,989.00 | — |
Average Common Equity |
17,722.00 | — | — |
Columns are period end dates